Your activity: 20 p.v.
Why UpToDate?
What's New
Patient Education
Calculators
Drug interactions
Subscribe
Log In
< Back
your limit has been reached. plz
Donate
us to allow your ip full access, Email: sshnevis@outlook.com
Uptodate Reference Title
Go To Link
Close
Diagnostic algorithm for identification of tropomyosin receptor kinase (TRK) fusions in solid tumors
Diagnostic algorithm for identification of tropomyosin receptor kinase (TRK) fusions in solid tumors
NGS: next-generation sequencing; IHC: immunohistochemistry.
* Tumor types with a >20% rate of TRK fusion positivity include congenital mesoblastic nephroma (CMN), infantile fibrosarcoma (IFS), mammary analogue secretory carcinoma (MASC) of the salivary gland, and secretory breast cancer (SBC).
¶ Tissue-relevant driver alterations include mutations in epidermal growth factor receptor (
EGFR
), anaplastic lymphoma kinase (
ALK
), c-ROS oncogene 1 (
ROS1
),
KRAS
,
NRAS
, and
BRAF
.
Δ Tumor types include non-small cell lung cancer, thyroid cancer, pancreatic cancer, cholangiocarcinoma, and sarcomas.
Graphic 126093 Version 3.0